471 results about "Hemoglobin H" patented technology

The present invention relates to an apparatus and method for the non-invasive analysis of physiological attributes, such as heart rate, blood pressure, cardiac output, respiratory response, body composition, and blood chemistry analytes including glucose, lactate, hemoglobin, and oxygen saturation. Using a combination of multi-functioning disparate sensors, such as optical and electrical, improvements are made over existing physiological measurement devices and techniques. The special configuration of one or more multi-functional sensors is used to non-invasively measure multi-wavelength optical plus one or more of ECG, Bio-impedance, and RF-impedance spectroscopic data. This information is used to develop self-consistent, non-linear algorithm in order to derive the physiological attributes while compensating for various forms of interfering effects including motion artifacts, sensor attachment variability, device component variability, subject physical and physiology variability, and various interfering physiological attributes.

The present invention is directed to the use of immunomodulatory compounds, particularly members of the class of compounds known as IMiDs™, and more specifically the compounds 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione and 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione, to induce the expression of fetal hemoglobin genes, genes essential for erythropoiesis, and genes encoding alpha hemoglobin stabilizing protein, within a population of CD34+ cells. These compounds are used to treat hemoglobinopathies such as sickle cell anemia or β-thalassemia, or anemias caused by disease, surgery, accident, or the introduction or ingestion of toxins, poisons or drugs.

Microvascular complications of diabetes mellitus are closely related to blood glucose levels and fluctuations. The Glycostator statistical package was created to allow patients and health care providers simple access to “glycemic indicators” which permit a “snapshot view” of the effectiveness of the patient's diabetes management program. Glycostator functions provide a simple way of enhancing the information already provided by home blood glucose monitoring devices. To this end, a set of new indices, including one called the Virtual A1c, are computed in a recursive fashion from blood glucose test results to provide a more meaningful day-to-day assessment of glycemic control. All indices can be made available at the meter user interface on request. The displayed indices allow patients to improve glycemic control by identifying problems with blood glucose control and lability that are less easily recognized in traditional blood glucose meter statistical packages. Virtual A1c emulates hemoglobin A1c continuously and provides better day-to-day assessment of long term glycemic control than does the traditional average blood glucose report. The method for computing each of these indices, including the Virtual A1c, allows for their implementation in commercial blood glucose monitors.

Methods of establishing hematopoietic chimerism useful to correct hematological diseases and promote acceptance of organ transplants include administering busulfan, costimulation blockade, and readily attainable numbers of T-cell depleted bone marrow cells.

In an emergency medicine patient, accurate measurement of change or lack thereof from non-shock, non-ischemimc, non-inflammation, non-tissue injury, non-immune dysfunction conditions is important and is provided, as practical, real-time approaches for accurately characterizing a patient's condition, using Raman spectroscopy with a high degree of accuracy, Resonance Raman spectroscopy is used to monitor tissue nitric oxide activity either in vivo or in vitro, especially as a function of its interaction with hemoglobin or other metalloproteins. Measurement times are on the order of seconds. High-accuracy measurement is achieved with Raman spectroscopy interrogation of tissue. Measurements may be non-invasive to minimally invasive. The invention may be used to monitor the effect of instituting therapies using nitric oxide or disease processes that produce nitric oxide.

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and / or cellular oxygenation.

Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and / or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.

The invention provides a hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit comprises an upper shell, a lower shell, an immunostrip, test paper and the like; a gold-labeled composite containing a hemoglobin monoclonal antibody, a hemoglobin-haptoglobin composite monoclonal antibody and a transferrin monoclonal antibody is scribed on a nitrocellulose membrane; 3 test lines, a quality control line (15) and a gold-labeled composite membrane scribing line (8) are arranged on the nitrocellulose membrane in parallel. The invention further provides a preparation method and a detection method of the hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit is convenient and simple in operation, stable in performance and accurate in result, has a relatively good reference value for early diagnosis and identification of colorectal cancer or colon cancer tumor or other tumors with lower gastrointestinal bleeding symptoms in clinic, significantly improves the positive detection rate of digestive hemorrhagic diseases, is suitable for clinical hospital examination and household self-examination, and provides measures for large-scale general examination of such diseases.

Provided are cycloalkyl- and cycloalkenyl-substituted benzaldehydes and heteroaldehydes of formula (I) that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions containing the modulators, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from increased tissue oxygenation.

A reagent for measurement of leukocytes and hemoglobin concentration in the blood includes a cationic surfactant in an amount sufficient to lyse erythrocytes and denature hemoglobin, at least one of the following hemoglobin stabilizers:(a) sulfosalicylic acid, or its salt, in an amount effective for promoting the conversion of hemoglobin into methemoglobin,(b) 0.2 to 10.0 g / L of a water-soluble chelating agent having a nitrogen atom and a carboxyl group, and(c) piperazine, or its salt, in an amount effective for promoting the conversion of hemoglobin into methemoglobin, anda buffer for maintaining pH at 4 to 6.

A method of measuring the stress or relaxation level of a mammal and a method of measuring the activity of the sympathetic nervous system of a mammal by measuring quantititative levels of deoxyhemoglobin and oxyhemoglobin are disclosed. Preferably, the levels of deoxyhemoglobin and hemoglobin are measured by a noninvasive technique, such as spectroscopy. A method of changing the activity of the sympathetic nervous system of a mammal is also disclosed, wherein the method includes a step of administering an effective amount of sensory regimen to the mammal. The method is useful for humans who are operating vehicles or machinery, who are suffering from cardiovascular disease or related complications, who are pregnant, or who are preparing for sleep. In addition, a method of improving the complexion of the skin of a mammal is disclosed.

The present invention relates to methods of treating subjects preparing to undergo surgery or methods of treating chronic disease and methods for reducing transfusions and a computer readable storage medium and a physical computing device for carrying out these methods which include: a) receiving a profile of said subject, in a physical computing device, including a level of hemoglobin of said subject, level of creatinine of said subject, and information regarding current or past history of disease; b) applying said level of hemoglobin and said level of creatinine, in said physical computing device, to determine level of transfusion risk; c) applying said information regarding current or past history of disease of said subject, in said physical computing device, to determine level of comorbidity; d) applying said level of hemoglobin, said level of transfusion risk, and said level of comorbidity, in said physical computing device, to determine a patient care plan.

A low cost portable high speed quantitative system for diffuse optical spectroscopic imaging of human tissue. The hybrid system (CWFD) can measure absolute optical properties from 660 nm to 980 nm and recover all tissue chromophore concentrations. The standalone FD module can be utilized to measure scattering at every measurement and recover deoxygenated and oxygenated hemoglobin concentrations. The CW module can operate concurrently with the FD module to also measure water and lipid. The high temporal resolution and large signal-to-noise ratio of the CWFD system may be used to explore tissue oximetry, vascular occlusion, and paced breathing models to measure and analyze tissue hemodynamics response to changes in blood flow. Continuous monitoring of vasculature response to various modified blood perfusion conditions can provide information about local tissue metabolism and physiological state (dysfunction).

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and / or cellular oxygenation.

The invention belongs to the technical field of preparation of platelet rich plasma and in particular discloses a method for preparing PRP (Platelet Rich Plasma) through a one-step centrifugation method. According to the method, only a high-speed automatic centrifuge is utilized, the one-step centrifugation method is adopted, only one-step liquor relief (which is used for absorbing plasma on a boundary layer) is required in the whole process, and the purposes of convenience, rapidness and low pollution risk are achieved. Moreover, according to the platelet rich plasma prepared by the method, a mean value of platelet cell concentrations reaches 1029.875*10<9> / L, the mean corpuscular hemoglobin in the PRP is 20.26 g / L, and the clinical requirements can be well met.

The invention provides a method of diagnosing tuberculosis (TB) in a test subject, said method comprising: (i) providing expression data of two or more markers in a subject, wherein at least two of said markers are selected from transthyretin, neopterin, C-reactive protein (CRP), serum amyloid A (SAA), serum albumin, apoliopoprotein-A1 (Apo-A1), apolipoprotein-A2 (Apo-A2), hemoglobin beta, haptoglobin protein, DEP domain protein, leucine-rich alpha-2-glycoprotein (A2GL) and hypothetical protein DFKZp667I032; and (ii) comparing said expression data to expression data of said marker from a group of control subjects, wherein said control subjects comprise patients suffering from inflammatory conditions other than TB, thereby determining whether or not said test subject has TB.

The invention relates to a kit and particularly relates to a kit for editing or repairing human hemoglobin gene. The kit comprises sgRNA of specific target HBB gene or a carrier containing the nucleotide sequence of the sgRNA; and / or modified Cas9 enzyme or a sequence encoding the modified Cas9 enzyme or a carrier containing the sequence encoding the modified Cas9 enzyme; and / or a donor gene sequence for repairing the HBB gene of beta-thalassemia or a carrier containing the donor gene sequence. The invention also provides an application of the kit in cutting or repairing the HBB gene, especially an application in repairing the HBB gene of autologous hematopoietic stem cells of a patient with beta-thalassemia. The kit provided by the invention has the advantages that the targeting capability of the target HBB gene is strong, the cutting efficiency of the HBB gene is high, the off-target efficiency is low, the HBB gene can be effectively repaired and the prospect in clinical study and treatment application is wide.

Method and pharmaceutical composition for treating anemia related symptoms. The method and formulation involve the use of one or more cucurbitacin analogs as active ingredients, for example, cucurbitacin D, which are capable of increasing hemoglobin expression, reactivating fetal or adult hemoglobin and inducing γ-globin.

A gastrointestinal bleeding noninvasive monitoring system belongs to medical apparatus technical field, wherein a miniature hemoglobin detecting device which enters into gastrointestinal tracts of human body through oral taking can realize 24-hour noninvasive detection of hemoglobin content value in gastrointestinal tracts and can transmit the value outside human body through wireless transmission; a bleeding spot locating device detects position information of the miniature hemoglobin detecting device and transmits detecting results to a record storage device through conducting wire; the record storage device receives gastrointestinal hemoglobin content value transmitted by the miniature hemoglobin detecting device through wireless transmission and stores data of gastrointestinal hemoglobin content value, position information of the miniature hemoglobin detecting device and detecting time information according to predetermined format; a gastrointestinal bleeding diagnosis-analysis system which is arranged outside human body reads and processes the data stored inside the record storage device. The invention can realize 24-hour noninvasive monitoring of gastrointestinal bleeding under normal physiological status of human body.

The present invention relates to various salts of inositol tripyrophosphate including the calcium, lithium, beryllium, magnesium, potassium, strontium, barium, rubidium and cesium salts of inositol tripyrophosphate, compositions comprising these salts, methods of making the various salts, and methods of use of the above salts. Methods of use include administering the above salts in an effective amount in individuals for the treatment of various types of cancers, Alzheimer's disease, stroke and osteoporosis.

Methods and apparatuses are disclosed for modifying images of skin so as to reduce or enhance the appearance of component pigments, such as melanin and hemoglobin. A diffuse reflectance image of skin, such as a cross-polarized contact dermoscopy image, which conveys information regarding subsurface features of the skin, is processed so as to extract pigment distribution information, which is then used to correct the diffuse reflectance image, such as by reducing the appearance of melanin to allow better visualization of hemoglobin-related structures, such as vasculature. Alternatively, the diffuse reflectance image can be corrected so as to reduce the appearance of hemoglobin to allow better visualization of melanin-related structures.

Blood information such as hemolysis (a plasma-free hemoglobin concentration) and a blood coagulation level (thrombus) can be obtained by extracting only reflected light in a plasma layer, and non-invasively and continuously obtaining information only on a plasma component independently of a hematocrit without separating blood components by a mechanical or chemical process. First measurement light 30 is caused to be incident on a boundary surface between blood 10 flowing through a flow cell 40 formed of a transparent material having a different refractive index from plasma (layer) 12 in the blood 10 and the flow cell 40, from an oblique direction at an angle smaller than 90 degrees. Reflected light 32 regularly reflected at the boundary surface between the flow cell 40 and the blood 10 is subjected to spectrometry. Information on a plasma component (a refractive index Np of plasma) is obtained from an absorption spectrum measured.

This invention relates to targeted delivery of anti-viral compounds through protein bioconjugation. More particularly, it relates to an anti-viral compound conjugated to a protein, such as hemoglobin and to a method of treating a viral infection using said conjugate. The invention also provides a method of targeted drug delivery of an anti-viral nucleoside analogue to macrophages, cells comprising a hemoglobin receptor and to CD163 bearing cells.

A blood cell analyzer diluent and a hemolytic agent, are characterized in that one litre diluent is provided with 12.0-4.0g of sodium chloride, 2.0-10.0g of sodium sulfate, 0.8-0.5g of 1,3,2-methylol urea, 0.2-0.5g of copper sulfite, 3.0-8.0g of EDTA-2Na, 0.2-0.7g of Piperacillin Sodium, a borate buffering liquid toning the ph value to 7.2-7.8, and the balance is water; one litre hemolytic agent is provided with 0.8-5.0g of potassium chloride, 0-60.0g of dodecyl trimethyl ammonium chloride, 14.0-0g of octadecyl trimethyl ammonium bromide, 6.0-10.0ml of isopropanol, carbonate or alcaine buffering liquid toning the ph value to 7.2-7.8, and the balance is water. The inventive reagent can form stable hemoglobin derivatives, and the absorption spectrum curves are similar when lambada is 540nm, lambada is 504nm, which can satisfy the clinical inspection requirement; the reagent does not contain cyanide, azide, and has non-toxicity, which can effective improve working atmosphere of operating staff, and can reduce harm of toxicant to personal health.